Oppenheimer analyst Steven Lichtman maintained a Buy rating on MannKind (MNKD – Research Report) today and set a price target of $5.50. The company’s shares closed yesterday at $3.34.
Lichtman covers the Healthcare sector, focusing on stocks such as RxSight, Boston Scientific, and Dexcom. According to TipRanks, Lichtman has an average return of 11.6% and a 52.85% success rate on recommended stocks.
MannKind has an analyst consensus of Strong Buy, with a price target consensus of $7.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $5.75 and a one-year low of $3.30. Currently, MannKind has an average volume of 2.54M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind (MNKD) Company Description:
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Read More on MNKD:
- MannKind management to meet with Cantor Fitzgerald
- Biotech Alert: Searches spiking for these stocks today
- MannKind reports Q3 EPS 1c, consensus (2c)
- MannKind options imply 9.3% move in share price post-earnings
- MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
